Table 1.
No barrier
|
Moderate barrier
|
Complete barrier
|
|||
---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | |
a) Regulatorya | 2.9% (1) | 8.6% (3) | 28.6% (10) | 48.6% (17) * | 11.4% (4) |
b) Specific aims/hypothesis | 11.4% (4) | 34.3% (12) | 45.7% (16) * | 8.6% (3) | 0.0% (0) |
c) Study design | 8.6% (3) | 25.7% (9) | 42.9% (15) * | 22.9% (8) | 0.0% (0) |
d) Grants | 5.7% (2) | 2.9% (1) | 28.6% (10) | 45.7% (16) * | 17.1% (6) |
e) Statistics/data analysis | 5.7% (2) | 14.3% (5) | 14.3% (5) | 54.3% (19) * | 11.4% (4) |
f) Study conduction/implementationb | 5.7% (2) | 22.9% (8) | 42.9% (15) * | 22.9% (8) | 5.7% (2) |
g) Ms. preparation/publication | 11.4% (4) | 31.4% (11) | 40.0% (14) * | 14.3% (5) | 2.9% (1) |
Data are percentages of total respondents (no. of respondents).
Ms.=manuscript.
Institutional Review Board approval, Fiscal Review, Clinical Trials Office, the Food and Drug Administration, or independent data safety monitoring.
Consenting procedure, data collection, organization, security.
Mode of all responses to each question.